Inozyme draws buy at Stifel on lead asset

seekingalpha09-12

Inozyme Pharma (NASDAQ:INZY) traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466727743?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg","is_english":true,"pubTime":"2024-09-12 20:33","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2466727743","market":"nz","top_or_hot":-1,"title":"Inozyme draws buy at Stifel on lead asset","media":"seekingalpha","content":"<div>\n<p>Inozyme Pharma (NASDAQ:INZY) traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a...</p>\n\n<a href=\"https://seekingalpha.com/news/4148980-inozyme-stock-draws-buy-stifel-lead-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inozyme draws buy at Stifel on lead asset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInozyme draws buy at Stifel on lead asset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 20:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4148980-inozyme-stock-draws-buy-stifel-lead-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inozyme Pharma (NASDAQ:INZY) traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a...</p>\n\n<a href=\"https://seekingalpha.com/news/4148980-inozyme-stock-draws-buy-stifel-lead-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://seekingalpha.com/news/4148980-inozyme-stock-draws-buy-stifel-lead-drug","article_id":"2466727743","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466727743","pubTimestamp":1726144413,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Inozyme Pharma  traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a pipeline-in-a-product. INZ-701 is an enzyme replacement therapy targeted at a trio of rare disorders, ENPP1 deficiency, calciphylaxis, and pseudoxanthoma elasticum , caused by deficiencies of inorganic pyrophosphate , a regulator of cellular function. \"Although lead indications are rare, we believe INZ-70 has a pipeline-in-a-product potential that a seasoned management team can extract maximal value from,\" Stifel analyst Dae Gon Ha wrote with a $16 price target on the stock. The analyst added that by year-end, Phase 1 interim data for INZ-70 from the SEAPORT 1 trial for calciphylaxis and the ENERGY 1 trial in infants with ENPP1 deficiency \"have a chance to instill investor confidence prior to additional catalysts in 2025. \"","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","INZY":"Inozyme Pharma","BK4139":"生物科技","PXE":"Invesco Energy Exploration & Production ETF","SF":"Stifel Financial Corp"},"translate_title":"Inozyme吸引Stifel买入主要资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INZY":1,"PXE":1,"SF":1},"content_text":"Inozyme Pharma (NASDAQ:INZY) traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a pipeline-in-a-product. INZ-701 is an enzyme replacement therapy targeted at a trio of rare disorders, ENPP1 deficiency, calciphylaxis, and pseudoxanthoma elasticum (PXE), caused by deficiencies of inorganic pyrophosphate ((PPi)), a regulator of cellular function. \"Although lead indications are rare, we believe INZ-70 has a pipeline-in-a-product potential that a seasoned management team can extract maximal value from,\" Stifel analyst Dae Gon Ha wrote with a $16 price target on the stock. The analyst added that by year-end, Phase 1 interim data for INZ-70 from the SEAPORT 1 trial for calciphylaxis and the ENERGY 1 trial in infants with ENPP1 deficiency \"have a chance to instill investor confidence prior to additional catalysts in 2025. \"","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466727743"}